menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Merck plans to launch US subcutaneous version of Keytruda

    REUTERS

    Mural Updates Ph III Nemvaleukin, Keytruda Trial In Ovarian Cancer

    GLOBENEWSWIRE

    First Patient Dosed In Immutep’s Ph III NSCLC Trial

    GLOBENEWSWIRE

    Evaxion to unveil phase 2 data for cancer vaccine at AACR Meeting

    GLOBENEWSWIRE

    BioInvent`s BI-1808 antibody featured at T-Cell Lymphoma Forum

    ACCESSWIRE

    BioInvent gets FDA Orphan Drug Designation for BI-1808 for T-cell

    ACCESSWIRE

    Merck`s Biologic Keytruda Receives Approval in US

    FDA

    BioCity, MSD Partner To Evaluate BC3195 + Keytruda In Solid Tumors

    PR NEWSWIRE

    Merck’s Injectable Keytruda Create Legal Dispute With Halozyme

    BIOSPACE

    Innovent Doses First Patient in IBI363 Melanoma Pivotal Study

    PR NEWSWIRE

    Microbiotica Shares MB097 Data in Advanced Melanoma

    PHARMAWEB

    Merck expects Keytruda to be part of government price

    REUTERS

    Medicenna Reports MDNA11’s Anti-Cancer Activity at AACR Conference

    GLOBENEWSWIRE

    FDA Grants Review To Merck’s Keytruda Combo For Head & Neck Cancer

    BUSINESSWIRE

    Ignite Proteomics To Present MHC-II Data On Pembrolizumab Response

    GLOBENEWSWIRE

    Bicara Begins Ph2/3 Ficerafusp Alfa Trial In Head, Neck Cancer

    GLOBENEWSWIRE

    Pfizer & Astellas Padcev + Keytruda Shows Efficacy in Cancer

    BUSINESSWIRE

    Pyxis Oncology Starts PYX-201 Combination and Monotherapy Trials

    GLOBENEWSWIRE

    Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer

    GLOBENEWSWIRE

    Merck, Eisai combo misses survival goal in GI cancer trial

    FIERCE PHARMA

    Adagene To Present Muzastotug Data With Keytruda At GI Symposium

    GLOBENEWSWIRE

    China`s NMPA Approves Padcev + Keytruda for Advanced Bladder Cancer

    PR NEWSWIRE

    Merck’s KEYTRUDA® Approved in China for NSCLC Neoadjuvant Treatment

    BUSINESSWIRE

    Merck`s Biologic Keytruda Receives Suppl Approval in US

    FDA

    BioNTech posts overall survival data on would-be Keytruda killer

    FIERCE BIOTECH

    Ideaya Starts Phase 1 Trial For IDE161 With KEYTRUDA® In Cancer

    PR NEWSWIRE

    Merck Announces Ph 3 KEYLYNK-001 Trial Success in Ovarian Cancer

    BUSINESSWIRE

    Medicenna Announces Complete Response in Study with KEYTRUDA®

    GLOBENEWSWIRE

    Merck Sharp`s Biologic Keytruda Receives Suppl Approval in US

    FDA

    Merck says Keytruda injection on par with approved IV version in trial

    FIERCE PHARMA

    Toragen Updates Data from Ph 1 Trial of TGN-S11 in HPV Cancers

    BUSINESSWIRE

    Merck Receives CHMP Opinion for KEYTRUDA® in MPM

    BUSINESSWIRE

    Citius Pharma Announces Promising Pembrolizumab Trial Results

    PR NEWSWIRE

    Medicenna Announces Positive MDNA11 Data with KEYTRUDA® at SITC

    GLOBENEWSWIRE

    BeyondSpring Presents Phase 2 Efficacy of Pembrolizumab Combo

    GLOBENEWSWIRE

    Hookipa Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

    GLOBENEWSWIRE

    Compugen to Present COM701, COM902 + Pembrolizumab Data at SITC

    PR NEWSWIRE

    Akeso Enrolls First Patient in Phase 3 HNSCC Trial with Ivonescimab

    PR NEWSWIRE

    Merck, Moderna Launch Phase 3 Trial for NSCLC Treatment

    BUSINESSWIRE

    Merck’s KEYTRUDA® Receives New Approvals For Gynecologic Cancers

    BUSINESSWIRE

    Exelixis And Merck Sign Clinical Development Collaboration

    BUSINESSWIRE

    Merck`s Keytruda stages comeback in head and neck cancer

    FIERCE PHARMA

    BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda

    FIERCE PHARMA

    ABL Bio Announces Clinical Collaboration For ABL103 with Keytruda

    PR NEWSWIRE

    Cue Biopharma Announces Presentations At SITC Annual Meeting

    GLOBENEWSWIRE

    Merus Doses First Patient In Ph 3 Trial Of Petosemtamab

    GLOBENEWSWIRE

    Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study

    PRESS RELEASE

    Merck`s KEYTRUDA Approved In Japan For NSCLC And Carcinoma

    BUSINESSWIRE

    Japan Approves PADCEV With KEYTRUDA For Urothelial Cancer

    PR NEWSWIRE

    Merck Receives Positive EU CHMP Opinions for KEYTRUDA

    BUSINESSWIRE

    FDA Approves KEYTRUDA Plus Pemetrexed Combo For Mesothelioma

    BUSINESSWIRE

    New Efti Combination Data To Be Presented For Sarcoma

    GLOBENEWSWIRE

    Antennova`s CD73 Inhibitor Shows 89.5% DCR At ESMO 2024

    PR NEWSWIRE

    PESG Reports On Nuvectis Pharma`s NXP900

    BUSINESSWIRE

    PDS Biotech Announces VERSATILE-002 Results At ESMO 2024

    GLOBENEWSWIRE

    NextCure Presented NC410 Phase 1b Results At ESMO 2024

    GLOBENEWSWIRE

    Keytruda Plus Chemo Reduces Death Risk In Early Breast Cancer

    BUSINESSWIRE

    Keytruda Shows Survival Win In Early Triple-Negative Breast Cancer

    FIERCE PHARMA

    Merck`s KEYTRUDA Demonstrates 10-Year Survival Benefit In Melanoma

    BUSINESSWIRE

    KEYTRUDA Plus CRT Reduces Death Risk In Cervical Cancer By 33%

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.